Course Hero has millions of student submitted documents similar to the one
below including study guides, practice problems, reference materials, practice exams, textbook help and tutor support.
Find millions of documents on Course Hero - Study Guides, Lecture Notes, Reference Materials, Practice Exams and more.
Course Hero has millions of course specific materials providing students with the best way to expand
their education.
Below is a small sample set of documents:
Rutgers - PHARM - 300
Diabetes mellitus y factores de riesgo asociados en la poblacin mexicana.M. En C. Zaira Ivonne Padrn Corts Secretara de SaludDEFINICIONLa Diabetes mellitus (DM) es una enfermedad crnica incurable, resultado de un desequilibrio entre la secrecin de insu
Rutgers - PHARM - 300
Age dependent type 1 diabetes pathogenesisAke LernmarkFrom Joerg Ermann & C. Garrison Fathman Nature Immunology 2, 759 - 761 (2001)InsulitisResidual -cell function in new onset Type 1 diabetesAge (years) 0-15 15-34rhw 5/99C-peptide level within nor
Rutgers - PHARM - 300
Diabetes and Cardiovascular Disease Epidemiology Clinical Trials ManagementNathan WongTM 1999 Professional Postgraduate ServicesDiabetes: Scope of Problem At least 10.3 million Americans have been diagnosed with diabetes mellitus, and another 5.4 mi
Rutgers - PHARM - 300
Vitamin D and risk of Type 1 diabetesDr Elina HyppnenMSc, MSc, MPH, PhDCentre for Pediatric Epidemiology and Biostatistics Institute of Child Health London, UKemail: e.hypponen@ich.ucl.ac.ukOverview Health effects of Vitamin D Type 1 diabetes Vitami
Rutgers - PHARM - 300
UniSMSc in Diabetes A population approachImpaired glucose tolerance and undiagnosed diabetesRoss LawrensonPostgraduate Medical School University of Surrey Metabolic syndrome Impaired glucose tolerance Undiagnosed Type 2 diabetesTheories on the aet
Rutgers - PHARM - 300
EPIDEMIOLOGY OF DIABETES ITS HISTORY IN THE LAST 50 YEARSProfessor Paul Zimmet, AO, MD, PhD, FRACP, FRCP(UK) International Diabetes Institute, Melbourne, AustraliaAbstractThe application of epidemiology to the study of diabetes mellitus has provided ne
Rutgers - PHARM - 300
D-Chiro-Inositol and its Role in Diabetes and Insulin ResistanceJoseph LarnerAllomed Pharmaceuticals TwoEnzyme Bioassays Initial Mediator Hypothesis and Search Inositol Glycans Isolated from Rat Liver Scale up to Beef Liver Isolate and Determine Nov
Rutgers - PHARM - 300
LOW CARBOHYDRATE, LOW INSULIN, MODERATE PROTEIN, HEALTHY FATS AS THE BASIS FOR BLOOD GLUCOSE NORMAIZATON IN DIABETESRON RAAB B.EC, PRESIDENT, INSULIN FOR LIFE AUSTRALIAMuch effort goes into refining insulin doses and types. But little focus seems to be
Rutgers - PHARM - 300
IFL r IFL IDD IFL 1,225,000 122,500 210,538 1,362,339 3,675,000 ($AUD 6,934,000) 6,934,000 16 123,000(1,230,000 ) 160,000 260,000 1 123,000 1.30 www.insulinforlife.org
Rutgers - PHARM - 300
K.A.P STUDY ON HT & DM INTRODUCTIONIn 2003, there were 189 million diabetic in the world. The global prevalence of Type-2 diabetes is expected to double in the period 20002025 and may reach a level of almost 324 million people. The "Top 10" countries of
Rutgers - PHARM - 300
TOTAL PATIENTS - 17512010080 No of patients6040200 Series1YES67NO108FAMILY HISTORY160HYPERTENSION & DIABETES140120No of patients100806040200 Series1Railway hospital149Private26Regular treatment Irregular treatm127 48TREATMENT
Rutgers - PHARM - 300
UPDATE ON CHILDHOOD DIABETES MELLITUSAbdelaziz Elamin MD, PhD, FRCPCH Professor of Child Health Sultan Qaboos UniversityDEFINITION The term diabetes mellitus describes a metabolic disorder of multiple etiologies characterized by chronic hyperglycemia
Rutgers - PHARM - 300
New Feature of NCEP ATP III:* Identification of the Metabolic SyndromePositive diagnosis based on the presence of three or more of the following:Risk FactorMen WomenDefining Level>102 cm (>40 in) >88 cm (>35 in) 150 mg/dL <40 mg/dL <50 mg/dL 130/ 85
Rutgers - PHARM - 300
NAT I ONAL PROGRAMA DI ABETES NACIONAL N E D UC AT O I EDUCACION EN DIABETES P R OGR AMCambiando la forma en que es tratada la diabetesPropsito de la sesin Actualizar las actividades de PNED Revisar los logros de grupos de trabajo raciales/tnicos Plane
Rutgers - PHARM - 300
2 Wilfred Y. Fujimoto Dxyer: 10 2 1980 0.67% 1996 3.21% 15 5 1600 2025 3700 Nikkei (DEFEND) NIDDM(GENNID) 15 2 2 (GENNID) Nikkei (DEFEND) 0% 50% urban W.Samoa W.Samoa Diabetes Care 16:157;1993 1970 2 2 16%~20% 4%~5% 2 2 2 2 2 2
Rutgers - PHARM - 300
2 Peter H. Bennett lpapple(DXY) 1998 2010 30-64 2 2 * * 2 2 1 47 89 73 55 6 59 Pima Pima 2 2 2 1978 1991 2 2 Pima 2 Pima 25-44 Pima 2 5 2 37-46 Pima 64 IGT 2 2 2 110 660 25-74 577 IGT 530 6 IGT 2
Rutgers - PHARM - 300
2 Peter H. Bennett DXY 2 A B 2 2 + 95 2 2 95 CI 2 6 <2.0 mg/kgMBS.min 2.0 - 5.0 mg/ kgMBS.min >5.0 mg/kgMBS.min 2 A B A B " " " " ( ) 1 22 2 2
Rutgers - PHARM - 300
Gwen256-DXY - - -- - - (SES) ( ) 051015 / 100, 000202530 ? - - - - DPP
Rutgers - PHARM - 300
Simon Weitzman, MD,MPH 1 GCT OGTT WHO NDDG Coustan (mg/dL) WHO 7 140 5g NDDG (100g) 105 195 180 1 2 200 165 155 145 140 3 Coustan 95 (100g) 50g >=186mgdL 38.2% 93.3% 78.6% 70.0%50g >=186mgdL 38.2% 93.3% 19.5% 97.2% VS 57.4% 27.7% 4
Rutgers - PHARM - 300
Patrick J O'Connor " 3 182,000 10-15 70% ASA 2 57% - 60 - 8 3 - 3 - 5 3 $60, 000 $50, 000 $40, 000 $30, 000 $20, 000 $10, 000 $0 6% 7% 8% HBAl c 9% >10%$8, 600 $9, 000 $9, 600$38, 700$40, 200$42, 500$45, 600$49, 700$10, 400 $11, 600 -
Rutgers - PHARM - 300
2000.12Gillian HawthorneHawthorne 1990 David Hadden Belfast Lois Jovanovic St Vincent 48/1000 8.9/1000 83/1000 21.3/1000 1000 Merseyside 1990 94 36.1 377.6 N/A9.7% 5% 1987 1996 11.8/1000 6.7/1000 28 7 16 1994 7 1 1997 6 30 24 >24
Rutgers - PHARM - 300
NIKOLA STOJANOVS KI EDEG EASD - 10 2.2 200/100000 1995 1.35 2025 20.25 88 90 2 2 2 20% >27kg/m2 >45 IFG IGT >140/90 mmHg <35mg/ml(0.90mmol/l) / <250 mg/ml(2.82mmol/l) 4.5kg 2 75 80 2 WHR "
Rutgers - PHARM - 300
John S Yudkin - Y2K 2000 10 6 - - ? + + + - PAI-1 6+C- + 6 24 6 6 PWHR HPA AXIS 6 CRP
Rutgers - PHARM - 300
Craig.Hanis,Ph.D. Hoaston 2001 23 & - - - - / - / - ? Starr 2 2 2 2 NIDDM1 NIDDM1 31kb 10 10 SNP 43,19,63 OGTT Sreenen et al,(2000).Diabetes 49 suppl 1:A62 10 10 FSIVGTT SNP 43,19.63 15
Rutgers - PHARM - 300
2 HNF-1a NIDDM1 10 - 15 3?2 MODY Chr.11 NDDM1Chr.7 Chr.11chr.9 chr.10Chr.15chr.3chr.21 - MODY Starr County Texas Eastern Finns GENNID FUSION San Antonio Utah Pima Indians Canadian Oji-Cree Old Order Amish ,3 , , , , , , , 49 27 , ADA/ Gh
Rutgers - PHARM - 300
Ake Lernmark Joerg Ermann & C.Garrison Fathman Nature Immunology 2,759-761(2001) C 0-15 15-34 20% 60% 10% 55% <5% 46% 90% 20 HLA DQ2,DQ8, DQ2/8 DQ6.2 35 INS VNTR 2.5% 5' CTLA-4 AT 2-3% 20-30% 10-15% ECHO ABO CBV4 T V- T1DM = (Varela-Calvino
Rutgers - PHARM - 300
Bruce W. Case, F.R.C.P.(C) MCGILL : : Bruce.Case@mcgill.ac http:/www.thename.org/causedeath/main.htm 1998 http:/cma.ca/cmaj/vol-158/issue-10/1317.htm 1960 1 2 17-18 3 19 a. Rokitansky( b. Virchow( c. Osler- d. 1 20 60 50% 2 10% 3 a.36.5% 1923
Rutgers - PHARM - 300
2 Abdullatif Husseini 2 2 2 2 2 2 2 11.1mmol/l ITG 2 7.8< 11.1mmol/l Last M 1995 Dictionary of epidemiology 2 " 2 1997 2000 6.2 5480 3.5 9960 2025 7.6 7220 4.9 22770 2 2 1 2 1 2 IGT,IFT,GDM. 2 Beaglhole " the
Rutgers - PHARM - 300
MSc I Ross LawrensonPostgraduate Medical School University of SurreyI ICA IAA , GADA 90 I 10 35 Atkinson MA Eisenbarth GS. Lancet 2001 358 221 9 1000 I I 0 4 5 9 10 14 15 19 100 000 1992 I 48 I 30 I 8.2 /100,000/ 21.5 /100,000/ I I Molba
Rutgers - PHARM - 300
/ Pe t e r M l gr o m DDS i 2 003 2 DXYer lesenhower / b e t a - b e t a - b e t a - b e t a - Be ve r l y A. Da l e - Cr unk, PhD Ri c ha r d J ur e vi c , DDS Nor ma W l l s , RDH, M e PH M r j or i e Ts ut s ui , De nt a l St ud a Na n
Rutgers - PHARM - 300
" " DXYer lesenhower 68 14 1926335N 38 c a uf i e l d Pe di a t r i c De nt i s t r y 1997. 19. 491- 8) " " Eva Sode r l i ng a nd p a ul i i s oka nga s Yl i vi e s ka Tu r ku 195 60 2 169 " " 6 147 4 2 . 2 6% 2 ) CHX) CHX 40 2 2 7. 5
Rutgers - PHARM - 300
- 50 Paul Zimmet,AO , , , ( ) , Resonance wang(dxy) , , , , .MAIMONIDES- " " " " West 1964 6 1964 20 1979 7 1980 8 (IDF) 1980 . . . Charles Dianne , John Jarrett- , . Ron LaPorte 20 80 . 1 . 200 . 1 . , (11) (12) 2 . Bedford(Hary keen),Whiteha
Rutgers - PHARM - 300
lpapple(DXY) 1999 1986-1999 1986 1986 IFL 1986 1,225,000 210,538 1,362,339 3,675,000 6,934,000 16 123,000 160,000 1 123,000 10 1.30
Rutgers - PHARM - 300
Metabolic Syndrome, Diabetes, and Cardiovascular Disease: Implications for Preventive CardiologyNathan D. Wong, PhD, FACC, FAHA Professor and Director Heart Disease Prevention Program Division of Cardiology University of California, IrvineOverview of Di
Rutgers - PHARM - 300
Evidence Supporting Aggressive Glycemic ControlTreatment of Type 2 DiabetesSites of Action of Therapeutic Options for Type 2 DiabetesDCCT: Effects of Intensive vs Conventional Glycemic ControlUKPDS: DesignUKPDS: Effects of Intensive (Sulfonylurea/Ins
Rutgers - PHARM - 300
Basic Considerations for Prevention of Blindness in Diabetes Care and EducationProf. Morsi Arab Emeritus Professor of Medicine University of AlexandriaPrevelance of DM in whole Egypt in Different Age Groups16 14 12 % population 10 8 6 4 2 0 0.62 0.80 3
Rutgers - PHARM - 300
Diabetes and Metabolic DiseasePaul R. EarlFacultad de Ciencias Biolgicas Universidad Autnoma de Nuevo Len San Nicols, NL 66450, Mexico pearl@dsi.uanl.mxNicolas PaulescuDiscoveryIn the middle of the 19th century, evidence from autopsies started to sug
Rutgers - PHARM - 300
DIABETES IN SUB-SAHARAN AFRICADr Kaushik RamaiyaThe future burden of diabetes in sub-Saharan Africa20 18 16 14 12 10 8 6 4 2 02030millions2025 2010Amos et al, 1997 WHO, King et al, 1998 WHO, Wild et al, 2003Africa is experiencing a rapid epidemiol
Rutgers - PHARM - 300
Modifiable Risk Factors for Type 2 Diabetes 2009 Middle Eastern Region Epidemiology Supercourse Alexandria, EgyptEdward Gregg, PhD Epidemiology and Statistics Branch Division of Diabetes Translation Centers for Disease Control and Prevention Atlanta, GA
Rutgers - PHARM - 300
Epidemiology of Type 2 Diabetes 2009 Middle Eastern Region Epidemiology Supercourse Bibliotheca Alexandria, EgyptEdward Gregg, PhD Epidemiology and Statistics Branch Division of Diabetes Translation Centers for Disease Control and Prevention Atlanta, GA
Rutgers - PHARM - 300
Dr. Tawfik A. M. KhojaMBBS, DPHC, FRCGP, FFPH,FRCP (UK) Director General - GCCRiyadh 11/1/1430H - 8/1/2009Dr. Tawfik A. Khoja 1 " (22 ) "" Is then one who Walks headlong, with his face Grovelling, better guided, Or one who walks Evenly on a Straight
Rutgers - PHARM - 300
Diabetes and Other Non-Communicable Diseases / EM Regional PerspectiveDr. Ibtihal Fadhil RA/ NCD/ Health promotion and Protection/ EMRO/WHOFirst BA Regional Workshop on the Epidemiology of Diabetes and Other Non-Communicable Diseases , Bibliotheca Alexa
Rutgers - PHARM - 300
Diabetes as a Global Health Problem The IDF meets the ChallengeBy Prof. Morsi Arab IDF Chairman MENA RegionMENAReported Incidence of Type1 Diabetes at the MENA Region per 100.000 population under 15 yrs ( Diabetes Atlas 2006) Afghanistan Algeria Bahra
Rutgers - PHARM - 300
Dr. Mona Hassan Ahmed Hassan Prof. BiostatisticsWhat to do before sitting to PC?Statistical Software How to generate and interpret results?Data CodingTransformation of qualitative information into Numbers OR SymbolsData PreparationEither the infor
Rutgers - PHARM - 300
Genetics of DiabetesJan Dorman, PhD University of Pittsburgh School of Nursing jsd@pitt.eduType 1 Diabetes (T1D)Type 1 DiabetesCaused by the destruction of the pancreatic beta cells Insulin is no longer produced Leads to hyperglycemia, ketoacidosis a
Rutgers - PHARM - 300
Integrating Genomics into Clinical PracticeJan Dorman, PhD University of Pittsburgh School of Nursing jsd@pitt.edu Applications of Genomics to Clinical PracticeMolecular diagnosis $1000 for human genome sequencePrediction of a healthy person's risk o
Rutgers - PHARM - 300
A Public Health Approach Towards Prevention of IDDMRonald E. LaPorte, University of PittsburghType I diabetes IncidencePRC MEX JPN Cuba PLD DEN UK US NOR SCO SWD CAN FIN 0 5 10 15 20 25 30 35 40Green mountains range beyond the northern wall White wate
Rutgers - PHARM - 300
WHO Collaborating CenterJanice Dorman, Ph.D. Director Molecular Epidemiology Ronald LaPorte, Ph.D. Director Disease Monitoring and TelecommunicationsGSPHThe Importance of IDDM RegistriesDiabetes Epidemiology Team in PittsburghY Allan Drash, M.D. Y Do
Rutgers - PHARM - 300
Cambridge 1983Cambridge Diabetes Epidemiology Course July, 1999 Thinking out of the boxNetwork Everyone in Prevention2009: A HEALTH ODYSSEYGlobal Life Expectancy20 years30 years40 years 70 yearsWHO DIAMOND Project100 Centers 50 CountriesIf Car
Rutgers - PHARM - 300
GLOBAL STRATEGIES FOR THE PREVENTION OF DIABETES AND OTHER NONCOMMUNICABLE DISEASESAla Alwan Assistant Director-General World Health OrganizationWorkshop on Epidemiology of Diabetes and Other Noncommunicable Diseases (Bibliotheca Alexandrina, 8 January
Rutgers - PHARM - 300
Epidemiology of 1 Diabetes Mellitus (T1DM) among children of Novosibirsk City, RussiaSazonova O.V., Simonova G.I., Shubnikov E.V., Galenok V.A., Vaskina E.A., Nikiforov O.A., Akopova A.G., Choubnikova J.M., Nikitin Yu.P. Novosibirsk State Medical Univers
Rutgers - PHARM - 300
TYPES OF STUDIES IN DIABETES EPIDEMIOLOGY :TYPES OF STUDIES BASED ON: : Purpose Time Cost FeasibilityTYPES OF STUDY Observational ) ) Descriptive Analytical Cross-sectional - Retrospective - Prospective - Experimental A STUDY DESIGN FOR THE OUTCOMES
Rutgers - PHARM - 300
(2009 8 ) / : 1948 193 %80 %60 : : , , , , , , , , , : -1 , - 2 -3 . : 1. 2. 3. 4. 5. 6. 7. : , ,
Rutgers - PHARM - 300
(II) 2009 - : : : Normal IGTType 2 DMComplications Disability Death : : " " - () : . 30 . . . . . Kahn et al., Nature, 2006 : 40 30%20 10 0l In di a ba nI nd ia Ur ba nF iji l n 52 00 al d l ra ba on i ze ra 19 20 Ru Ru po g
Rutgers - PHARM - 300
Sntomas emocionales y prctica sexual de pacientes con diabetes mellitus tipo 2 y controles sanos M.C.M. Mara de Lourdes Garca Campos Facultad de Enfermera y Obstetricia de Celaya Universidad de Guanajuato Y Dra. Mara Raquel Huerta Franco Universidad de G
Rutgers - PHARM - 300
PhD Public Health, Suez Canal University, Egypt Diabetes MSc, Cardiff University, United Kingdom Dr. Rasha SalamaDiabetes mellitus (DM) is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, in
Rutgers - PHARM - 300
Diabetes Self ManagementLaura WintersteenArleth, MN, RN,CDELearning Objectiveso Understand the impact of diabetes o Distinguish the different types of Diabetes o Identify treatment options for diabetes management o Identify methods of applying the Chro
Rutgers - PHARM - 300
Diabetic KetoacidosisAbdelaziz Elamin Professor of Pediatric Endocrinology University of Khartoum, SudanIntroductionDKA is a serious acute complications of Diabetes Mellitus. It carries significant risk of death and/or morbidity especially with delayed
Drexel - MUSIC - MUS130
Introduction to MusicMUSC 130 2:00-2:50 Nesbitt 111Instructor: Mr. Bruce Kaminsky. Office: MacAlister 2012.Phone (215) 895-2451 email: bk46@drexel.eduDescription: Course objectives: learn principal musical genres influencing western music from antiqu
Shanghai Normal University - ACC - 410
1 2 3
Shanghai Normal University - ACC - 410
1 2 3 4 5 1 1 A B